Kanako Kasuya

Kanako Kasuya

Auto-generated profile, based on publicly available information

Kanako Kasuya

Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Osaka, Japan

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 January 2025 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
YWYan Wang
Yan Wang
YKYasuto Kinose
Yasuto Kinose
KKKanako Kasuya
Kanako Kasuya
MKMai Koizumi
Mai Koizumi
ASAasa Shimizu
Aasa Shimizu
TKTadashi Kimura
Tadashi Kimura
Ovarian clear-cell carcinoma (OCCC), particularly advanced or recurrent settings, is generally resistant to platinum-based chemotherapy, warranting novel therapeutic strategies. Mutations in the PI3K/AKT/mTOR pathway are frequently reported in OCCC. Therefore, we hypothesized that the PI3K/mTOR dual inhibitor, GSK458, and arsenic trioxide (As2O3) may exert synergistic antitumor effects on OCCC. We investigated the effects of GSK458, As2O3, and the combination of GSK458 and As2O3 on cell viability, colony formation, and apoptosis in seven OCCC cells. Mechanistically, transcriptomic differences were assessed among the groups. Additionally, their antitumor effects were evaluated on the three-dimensional cultures of OCCC patient-derived xenografts as well as in vivo. Low-dose combination of GSK458 and As2O3 exerted synergistic antitumor effects in vitro. Viability of the three-dimensional OCCC patient-derived xenograft cultures treated with the combination of GSK458 and As2O3 decreased to 23.8% of that of the control. RNA sequencing revealed that the mechanism was associated with cell cycle and DNA damage repair. The combination of GSK458 and As2O3 synergistically inhibited the PI3K/AKT/mTOR pathway and angiogenesis and increased apoptosis. Compared with any monotherapy, the combination treatment significantly suppressed tumor growth in vivo, thereby enhancing survival. Overall, our findings highlight the potential of the novel combination of GSK458 and As2O3 for OCCC treatment.

17 June 2026
Verified
Other
Open access
YWYan Wang
Yan Wang
YKYasuto Kinose
Yasuto Kinose
KKKanako Kasuya
Kanako Kasuya
MKMai Koizumi
Mai Koizumi
ASAasa Shimizu
Aasa Shimizu
TKTadashi Kimura
Tadashi Kimura
The effect on DNA damage activated by GSK458-As2O3 plus olaparib or carboplatin in OCCC cells.


17 June 2026
Verified
Other
Open access
YWYan Wang
Yan Wang
YKYasuto Kinose
Yasuto Kinose
KKKanako Kasuya
Kanako Kasuya
MKMai Koizumi
Mai Koizumi
ASAasa Shimizu
Aasa Shimizu
TKTadashi Kimura
Tadashi Kimura
Combination treatment with GSK458 and As2O3 shows anti-tumor effects in OCCC cells. Figure.

17 June 2026
Verified
Other
Open access
YWYan Wang
Yan Wang
YKYasuto Kinose
Yasuto Kinose
KKKanako Kasuya
Kanako Kasuya
MKMai Koizumi
Mai Koizumi
ASAasa Shimizu
Aasa Shimizu
TKTadashi Kimura
Tadashi Kimura
The effect on DNA damage activated by GSK458-As2O3 plus olaparib or carboplatin in OCCC cells.

2 April 2025
Verified
Other
Open access
YWYan Wang
Yan Wang
YKYasuto Kinose
Yasuto Kinose
KKKanako Kasuya
Kanako Kasuya
MKMai Koizumi
Mai Koizumi
ASAasa Shimizu
Aasa Shimizu
TKTadashi Kimura
Tadashi Kimura
Heatmap of angiogenesis-related genes and autophagy-related genes from RNA sequence after combinaton treatment with GSK458 and As2O3.